Immuneering Corporation (IMRX)

NGM – Real Time Price. Currency in USD

4.76

+0.23 (5.08%)

At close: Jun 26, 2026, 4:00 PM EDT

4.76

-0.00 (-0.01%)

After-hours: Jun 26, 2026, 7:57 PM EDT

15.06.2026

Immuneering Appoints Andrew Gengos as Chief Financial Officer

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion.

12.06.2026

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.

11.06.2026

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall survival, anticipated in mid-2028 NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patients. Atebimetinib is a novel MEK inhibitor with a pulsatile mechanism designed to target RAS, RAF, and other MAPK pathway-driven cancers with greater durability and tolerability than traditional chronic inhibitors.

01.06.2026

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

01.06.2026

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can

21.05.2026

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

15.05.2026

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now recruiting (NCT07562152), with first patient dosing on track for mid-2026 - - 27 months progression-free survival to date in a third-line pancreatic cancer patient receiving atebimetinib monotherapy, with an ongoing 85% reduction in tumor burden – - Ended Q1 2026 with $198.6 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 - NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the first quarter ended March 31, 2026, and provided business updates. "We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral presentation at the ASCO Annual Meeting on June 1st,” said Ben Zeskind, Chief Executive Officer of Immuneering.

Videos

No Data

There is no data to display

Press releases

15.06.2026

Immuneering Appoints Andrew Gengos as Chief Financial Officer

11.06.2026

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

01.06.2026

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can

21.05.2026

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Corporation (IMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immuneering Corporation (IMRX)

Immuneering Appoints Andrew Gengos as Chief Financial Officer

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Appoints Andrew Gengos as Chief Financial Officer

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Search stocks

Immuneering Corporation (IMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immuneering Corporation (IMRX)

Immuneering Appoints Andrew Gengos as Chief Financial Officer

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Appoints Andrew Gengos as Chief Financial Officer

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy